Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

Doubrovina, Ekaterina; Oflaz-Sozmen, Banu; Prockop, Susan E.; Kernan, Nancy A.; Abramson, Sara J.; Teruya‐Feldstein, Julie; Hedvat, Cyrus V.; Chou, Joanne F.; Heller, Glenn; Barker, Juliet N.; Boulad, Farid; Castro‐Malaspina, Hugo; George, Diane; Jakubowski, Ann A.; Koehne, Guenther; Papadopoulos, Esperanza B.; Scaradavou, Andromachi; Small, Trudy N.; Khalaf, Ramzi; Young, James W.; O’Reilly, Richard J.

doi:10.1182/blood-2011-08-371971

Cited by 381 publications

(396 citation statements)

References 41 publications

Supporting

Mentioning

377

Contrasting

Unclassified

Order By: Relevance

“…Potential solution in this scenario is the so called "third party bio-banks" of VSTCs where they can be selected by HLA haplotypes [105]. The first multicenter trial of ATCT with cells obtained from banked third-party VSTCs for the treatment of refractory viral infections after HSCT was reported by Leen et al in 2013 [106].…”

Section: Recent Developments: Third-party Vstcs and Naïve Donors T-cementioning

confidence: 99%

Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

Madon

Giaccone

Festuccia

et al. 2016

Expert Review of Hematology

View full text Add to dashboard Cite

Section: Recent Developments: Third-party Vstcs and Naïve Donors T-cementioning

confidence: 99%

Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

Madon

Giaccone

Festuccia

et al. 2016

Expert Review of Hematology

View full text Add to dashboard Cite

“…In the adult donor setting, virus-specific T-cells (VSTs) can be generated from the donor, either by culture with modified APCs [82][83][84][85][86][87] or peptide multimers. 88,89 Rapid isolation strategies such as 'gamma catch' can be utilized when VSTs occur at high frequency in the donor's blood.…”

Section: Infectionmentioning

confidence: 99%

Umbilical cord blood graft engineering: challenges and opportunities

Thompson

Rezvani

Hosing

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specificT-cells or chimeric-antigen receptor T-cells which are reviewed in this study.

show abstract

“…(Taylor et al 2015) The most immunogenic of these is post-transplant lymphoproliferative disease and many studies have shown that infusions of EBV-specific T-cells derived from an EBV seropositive normal HSCT donor can induce complete remission in over 70% of patients who develop this complication after HSCT. (Bollard and Heslop 2016, Doubrovina et al 2012, Heslop et al 2010) Initial manufacturing strategies for donor-derived EBV-specific T-cells were lengthy, because they used lymphoblastoid cell lines (LCLs) as a source of EBV antigen. With the availability of overlapping peptide libraries spanning individual EBV antigens, several groups have shortened the process and shown that rapidly expanded EBV-specific T-cells induce similar response rates.…”

Section: Targeting Tumour-associated Antigens With Native T-cell Recementioning

confidence: 99%

“…This approach has been tested in the clinic in patients with EBV-associated post transplant lymphoma with response rates of 60–80%. (Doubrovina et al 2012, Haque et al 2007, Leen et al 2013, Vickers et al 2014)…”

Section: Targeting Tumour-associated Antigens With Native T-cell Recementioning

confidence: 99%

Recent advances in T‐cell immunotherapy for haematological malignancies

et al. 2016

View full text Add to dashboard Cite

In vitro discoveries have paved the way for bench-to-bedside translation in adoptive T cell immunotherapy, resulting in remarkable clinical responses in a variety of haematological malignancies. Adoptively transferred T cells genetically modified to express CD19 CARs have shown great promise, although many unanswered questions regarding how to optimize T-cell therapies for both safety and efficacy remain. Similarly, T cells that recognize viral or tumour antigens though their native receptors have produced encouraging clinical responses. Honing manufacturing processes will increase the availability of T-cell products, while combining T-cell therapies has the ability to increase complete response rates. Lastly, innovative mechanisms to control these therapies may improve safety profiles while genome editing offers the prospect of modulating T-cell function. This review will focus on recent advances in T-cell immunotherapy, highlighting both clinical and pre-clinical advances, as well as exploring what the future holds.

show abstract

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

Cited by 381 publications

References 41 publications

Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation

Umbilical cord blood graft engineering: challenges and opportunities

Recent advances in T‐cell immunotherapy for haematological malignancies

Contact Info

Product

Resources

About